Affinity Life Sciences Announces Partnership with Prediction Sciences To Develop And Produce Cellular Fibronectin Elisa Kit - Affinity Life Sciences
696
post-template-default,single,single-post,postid-696,single-format-standard,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-theme-ver-9.1.2,wpb-js-composer js-comp-ver-4.11.2,vc_responsive
 

Affinity Life Sciences Announces Partnership with Prediction Sciences To Develop And Produce Cellular Fibronectin Elisa Kit

14 Jun Affinity Life Sciences Announces Partnership with Prediction Sciences To Develop And Produce Cellular Fibronectin Elisa Kit

Milford, NH. Prediction Sciences and Affinity Life Sciences , today announced a development and commercialization agreement of a biomarker assay, cellular fibronectin; for the identification and use of a research diagnostic marker for stroke, vascular damage and hemorrhagic transformation (HT). Upon completion of development and validation of the biomarker, Affinity will manufacture the cellular fibronectin ELISA kits exclusively for Prediction Sciences.

This agreement provides Prediction Sciences with an opportunity to utilize Affinity’s extensive experience in biomarker development and production of high-quality diagnostic reagents and products. Prediction’s easy-to-use microplate ELISA test will be a valuable tool for academic and pharmaceutical researchers interested in cellular fibronectin.

Tod Gavron, President of Affinity Life Sciences , stated “We are very pleased that Prediction Sciences has continued our long-term relationship on the development of a cellular fibronectin assay and the production of their novel diagnostic test. We look forward to Prediction Sciences’ successful commercial launch of this unique biomarker.”

“We are delighted to be able to partner with a company as dynamic as Affinity on our cellular fibronectin assay and are looking forward to advancing this diagnostic product”, said Albert Man, Director of Business Development at Prediction Sciences. “The development, verification, and production of this ELISA test for cellular fibronectin demonstrates a positive step toward the eventual clinical utility of this assay for cardiovascular disease and cerebral injury.”

About Prediction Sciences, LLC
Prediction is a privately held company developing and marketing novel tests of molecular and immunoassay diagnostics for disease detection, prognosis, and treatment. The company provides a Breast Cancer Profile to determine risk of recurrence in patients with operable breast cancer, and have products in development for Colorectal Cancer and Stroke. Prediction Sciences, LLC was founded in 2000 and is based in La Jolla, California. Visit Prediction at predict.net or contact Albert Man ataman@predict.net to learn more.

About Affinity
Affinity Life Sciences is a Contract Research and Manufacturing Organization providing R&D, testing, manufacturing, lyophilization, and commercialization services for the diagnostic and pharmaceutical industries. Affinity specializes in biomarker and immunochemistry assay development, purification and conjugation services, lyophilization services and a multitude of support services for either research or cGMP projects. Visit Affinitylifesciences.com or contact Sales at +1(603) 249-1644 ext.102 or info@afflif.com to learn more about Affinity’s custom services.

No Comments

Sorry, the comment form is closed at this time.